Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Publication | Closed Access

DOI

Citations

References

2017

Year

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo, José Ramón Arribas, Joseph Gathe, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic,

The Lancet HIV

Protease InhibitorsTreatment And PreventionPharmacologyClinical TrialsAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyNon-inferiority TrialTenofovir AlafenamideHivAntiviral DrugMedicine